Study of persistent low-level HIV in people on treatment
Part of Infections clinical trials.
This study looks at why some people with HIV on antiretroviral therapy still have small amounts of virus in their blood, while others achieve undetectable levels. Researchers will compare the two groups to understand the virus and immune system, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been on HIV antiretroviral therapy (ART) for at least 3 years.
- You must be taking one of the listed HIV medication combinations.
- You must have either had 3 or more low-level viral loads (50–1,000 copies/mL) over the past year, or 3 or more undetectable viral loads (below 50 copies/mL) over the past 2 years.
- You must not have any HIV drug resistance mutations to your current medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers in the blood that help some people with HIV stay virus-free without medication for a long time. If you have controlled your HIV without drugs for at least 6 months, or are interested in pausing your medication to see if you can control the virus, this study may help guide future treatments.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
This study looks at the hidden virus and immune system in people living with HIV who can control the virus without medication or after certain treatments. It aims to understand why some people control HIV better, which could lead to new treatments.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.